Azopt

Country of origin - United States of America
Pharm-Group - Antiglaucoma drugs

Manufacturers - Alcon-Laboratory (United States of America)
International name - Brinzolamide
Dosage forms - ophthalmic suspension 1%
Composition - Active substance - brinzolamide.
Indications for use: Increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Contraindications - Hypersensitivity. Restrictions on use. Pregnancy, breastfeeding, childhood.
Side effects - Blurred vision, blepharitis, dermatitis, dry eyes, sensation of a foreign body in the eye, headache, hyperemia, discharge from the eyes, discomfort in the eyes, keratitis, pain and itching in the eyes, conjunctivitis, diplopia, dizziness, asthenopia, keratoconjunctivitis, keratopathy, the first signs of blepharitis (a feeling of sticking together of the eyelids or a crust on the edges of the eyelids), lacrimation; rhinitis, shortness of breath, pharyngitis; bitter, sour or unusual taste in the mouth, diarrhea, dry mouth, dyspepsia, nausea; allergic reactions, urticaria, alopecia, chest pain, hypertension, kidney pain.
Interaction - Possibility of enhancing known systemic effects associated with carbonic anhydrase inhibition in patients receiving carbonic anhydrase inhibitors orally and topically (simultaneous use of instilled brinzolamide and oral carbonic anhydrase inhibitors is not recommended).
Overdose - When taken orally, the following symptoms may occur: electrolyte imbalance, acidosis, nervous system disorders. Treatment: symptomatic, it is necessary to monitor the level of electrolytes (especially potassium) in the blood and control the blood pH value.
Special instructions - Brinzolamide is a sulfonamide and, although applied topically, is subject to systemic absorption. In this regard, when using brinzolamide in the form of eye drops, adverse reactions characteristic of sulfonamides may occur. If serious adverse reactions occur or if hypersensitivity occurs, use should be discontinued. In rare cases, changes in acid-base and electrolyte balance have been reported when oral carbonic anhydrase inhibitors were administered with large doses of salicylates. Therefore, when treating with brinzolamide, the possibility of such drug interactions in patients should be taken into account. In patients with acute angle-closure glaucoma, in addition to the drugs used for ocular hypertension, additional therapeutic measures are required. Since brinzolamide (and its metabolite) is excreted primarily through the kidneys, it is not recommended for this pathology. Brinzolamide should be used with caution in patients with impaired liver function. Caution should be exercised when driving vehicles and operating equipment (due to the possibility of temporary blurred vision after instillation). Before using the drug, contact lenses should be removed and put on no earlier than 15 minutes after instillation.
Literature - Encyclopedia of Medicines 2005